Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Priapism

Prolonged Pathological Erection, A Urological Emergency

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Recognized adverse effect (ICI agents, PDE5 inhibitors)

Reference only. Not medical advice.

What can go wrong

Ischemic priapism lasting more than four hours is a urological emergency, delay risks irreversible cavernosal fibrosis and permanent erectile dysfunction. Highest risk is with intracavernosal injection therapy, where dose titration under supervision matters; PDE5 inhibitors carry a lower but real risk; men with sickle cell disease are predisposed. Treatment escalates from aspiration and intracavernosal sympathomimetics to surgical shunting. Patients must be counseled to seek immediate care.

This is something to take to a clinician. The Atlas can tell you what is known about priapism in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Priapism is a persistent erection unrelated to or outlasting sexual stimulation. The ischemic (low-flow) form is a urological emergency: lasting beyond four hours it risks cavernosal tissue ischemia, fibrosis, and permanent erectile dysfunction. It is most associated with intracavernosal injection (ICI) therapy, and also with PDE5 inhibitors, sickle cell disease, and certain medications. Immediate medical attention is required.

An erection lasting more than four hours is not a punchline, it is an emergency.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Recognized adverse effect of erectile dysfunction therapies

How it works

Ischemic (low-flow) priapism results from impaired venous outflow from the corpora cavernosa, trapping deoxygenated blood. Prolonged stasis causes a compartment-syndrome-like state with acidosis, hypoxia, and eventually smooth-muscle necrosis and fibrosis. Intracavernosal vasoactive agents (alprostadil, papaverine, phentolamine) can over-relax cavernosal smooth muscle; PDE5 inhibitors prolong cGMP-mediated relaxation; sickle cell disease causes red-cell sludging that obstructs outflow.

Safety in detail

An erection lasting more than four hours requires immediate emergency medical care. Erectile dysfunction therapies that can cause priapism require evaluation and dose titration by a qualified physician.

  • Ischemic priapism >4 hours is a urological emergency
  • Highest association: intracavernosal injection therapy
  • Also linked to PDE5 inhibitors and sickle cell disease
  • Untreated: cavernosal fibrosis and permanent ED
  • Treatment ladder: aspiration, intracavernosal sympathomimetic, surgical shunt

What people get wrong

  • Often saidA long-lasting erection just means the drug worked well

    ActuallyAn erection beyond four hours is ischemic priapism, an emergency that can cause permanent erectile dysfunction without prompt treatment.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

At a glance

Emergency threshold
>4 hours (ischemic)
Most associated treatment
Intracavernosal injection (ICI)
Other causes
Sickle cell disease, PDE5 inhibitors, drugs
Untreated risk
Cavernosal fibrosis, permanent ED

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Priapism. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • AUA Guideline on the management of priapism2003

    Established ischemic priapism beyond 4 hours as an emergency and defined the aspiration/sympathomimetic/shunt treatment ladder

  • Broderick et al., Journal of Sexual Medicine, priapism pathophysiology and management2010

    Characterized ischemic vs non-ischemic priapism and time-dependent tissue injury